Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for patients with non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this novel approach.
• Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
• Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
• Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
• Assess the biological basis for and recently presented research findings with perioperative anti-PD-1 antibody therapy in combination with antibody-drug conjugate therapy for patients with MIBC who are ineligible for cisplatin-based chemotherapy, and consider the potential role of this novel approach in clinical practice.
• Analyze the scientific justification for the use of perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this therapeutic strategy.
• Understand the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in MIBC, and evaluate emerging research documenting the benefit of adjuvant anti-PD-1/PD-L1 antibody therapy for patients with detectable ctDNA after cystectomy.
• Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.